Search

Your search keyword '"C Rojas Hopkins"' showing total 3 results
Start Over Author "C Rojas Hopkins"
3 results on '"C Rojas Hopkins"'

1. Significant differences in access to tests and treatments for multiple myeloma between public and private systems in Latin America. Results of a Latin American survey. GELAMM (Grupo de Estudio Latino Americano de Mieloma Múltiple)

Author

Dorotea Fantl, Hernán López-Vidal, Natalia Schutz, Virginia Bove, Juan Ramón Benito Navarro, Y Rubio, Eloisa Riva, Camila Peña, H Martínez, Fiorella Villano, Guillermo J. Ruiz-Argüelles, C Rojas Hopkins, J Ramirez, L Suárez, L Andino, Juan Antonio Choque, O Da Costa, and M Rodriguez Pineda

Subjects
education.field_of_study, Latin Americans, Incidence (epidemiology), Population, Hematology, General Medicine, World population, medicine.disease, 03 medical and health sciences, 0302 clinical medicine, Geography, 030220 oncology & carcinogenesis, medicine, In real life, education, Multiple myeloma, 030215 immunology, Demography
Abstract

The incidence of multiple myeloma (MM) has increased in the last 20 years, particularly in middle and low-middle income countries. Access to diagnostic and prognostic tests and the availability of effective care is highly variable globally. Latin America represents 10% of the world population, distributed in countries of varied size, population, and socio-economic development. In the last decade, great improvements have been made in the diagnosis and treatment of MM. Applying these advances in real life is a challenge in our region. Local data regarding MM standards of care and outcomes are limited. A survey was carried out among hematologists from 15 Latin American countries to describe access to MM diagnostic and prognostic tests and the availability of effective care options. This study provides real-world data for MM in our region, highlighting striking differences between public and private access to essential analyses and therapeutic options.

Published
2020
Full Text
View/download PDF

2. Significant differences in access to tests and treatments for multiple myeloma between public and private systems in Latin America. Results of a Latin American survey. GELAMM (Grupo de Estudio Latino Americano de Mieloma Múltiple)

Author

Eloísa, Riva, N, Schütz, C, Peña, G, Ruiz-Argüelles, C Rojas, Hopkins, V, Bove, F, Villano, L, Andino, L, Suárez, H, Martínez, J, Navarro, H, López-Vidal, O, Da Costa, M Rodriguez, Pineda, Y, Rubio, J, Ramirez, J, Choque, and D, Fantl

Subjects
Cross-Sectional Studies, Latin America, Surveys and Questionnaires, Public Health Practice, Private Practice, Multiple Myeloma, Health Services Accessibility
Abstract

The incidence of multiple myeloma (MM) has increased in the last 20 years, particularly in middle and low-middle income countries. Access to diagnostic and prognostic tests and the availability of effective care is highly variable globally. Latin America represents 10% of the world population, distributed in countries of varied size, population, and socio-economic development. In the last decade, great improvements have been made in the diagnosis and treatment of MM. Applying these advances in real life is a challenge in our region. Local data regarding MM standards of care and outcomes are limited. A survey was carried out among hematologists from 15 Latin American countries to describe access to MM diagnostic and prognostic tests and the availability of effective care options. This study provides real-world data for MM in our region, highlighting striking differences between public and private access to essential analyses and therapeutic options.

Published
2019

3. Different outcomes for transplant-eligible newly diagnosed multiple myeloma patients in Latin America according to the public versus private management: a GELAMM study.

Author

Peña C, Riva E, Schutz N, Tarín-Arzaga L, Martínez-Cordero H, Bove V, Osorio R, Chandía M, Beltrán C, Schulz J, Cardemil D, Contreras C, Vergara CG, Donoso J, Espinoza M, La Rocca G, López-Vidal H, León P, Rojas Hopkins C, Soto P, Aranda S, Torres V, Roa M, Ochoa P, Duarte PJ, Remaggi G, Yantorno S, Corzo A, Zabaljauregui S, Shanley C, Lopresti S, Orlando S, Verri V, Quiroga L, García C, Fernández V, Ramirez J, Molina A, Pacheco M, Mite A, Reyes I, Sabando B, Ramírez F, Sossa C, Abello V, Idrobo H, Galvez Cardenas KM, Saavedra D, Quintero G, Gazitúa R, Gaviria L, Gomez R, Osuna M, Henao-Uribe A, Cantú-Martínez O, Gómez-Almaguer D, García-Navarrete YI, Cruz-Mora A, Cantero-Fortiz Y, Ruiz-Argüelles GJ, and Fantl D

Subjects
Antineoplastic Combined Chemotherapy Protocols therapeutic use, Humans, Latin America epidemiology, Transplantation, Autologous, Treatment Outcome, Hematopoietic Stem Cell Transplantation, Multiple Myeloma diagnosis, Multiple Myeloma epidemiology, Multiple Myeloma therapy
Abstract

The aim of this study was to describe clinical and survival characteristics of transplant-eligible multiple myeloma (MM) patients in Latin America (LA), with a special focus on differences between public and private healthcare facilities. We included 1293 patients diagnosed between 2010 and 2018. A great disparity in outcomes and survival between both groups was observed. Late diagnosis and low access to adequate frontline therapy and ASCT in public institutions probably explain these differences. Patients treated with novel drug induction protocols, followed by autologous stem cell transplantation (ASCT) and maintenance, have similar overall survival compared to that published internationally.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results